Drugs / ENFORTUMAB VEDOTIN
ENFORTUMAB VEDOTIN
also known as
AGS-22CE · AGS-22M6E · AGS-22ME · AGS-22MSE · Asg-22ce · ASG-22ME · Enfortumab vedotin ejfv · Enfortumab vedotina · +2 more
Monoclonal antibody targets NECTIN4
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01409135 | Jul 2011 → Apr 2015 | neoplasm | Astellas Pharma Inc | Completed | No outcome recorded |
Press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-10 | Pfizer | U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-04-20 | Pfizer | U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-02-27 | Pfizer | PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer pfizer.com ↗ |
| 2025-12-17 | Pfizer | PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2025-11-21 | Pfizer | U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer pfizer.com ↗ |
| 2025-10-18 | Pfizer | PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer pfizer.com ↗ |
| 2025-08-12 | Pfizer | PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery pfizer.com ↗ |
| 2025-02-10 | Pfizer | Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) pfizer.com ↗ |
| 2024-01-26 | Pfizer | European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer pfizer.com ↗ |
| 2023-12-15 | Pfizer | PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer pfizer.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENFORTUMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | AGS-22CE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | AGS-22M6E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01409135 ↗ |
| Known as | AGS-22ME | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | AGS-22MSE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | Asg-22ce | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | ASG-22ME | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | Enfortumab vedotin ejfv | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | Enfortumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | Enfortumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Known as | Padcev | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301589 ↗ |
| Modality | Monoclonal antibody | “AGS-22M6E and ASG-22CE are fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE)” NCT01409135 ↗ |
| Route | Intravenous | “IV Infusion” NCT01409135 ↗ |
| Target | NECTIN4 | “Nectin-4 binding agent” CHEMBL3301589 ↗ |